Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S7NS
|
|||
| Former ID |
DIB010337
|
|||
| Drug Name |
MMI-0100
|
|||
| Synonyms |
Peptide MAPKAPK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix; Peptide MK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix
Click to Show/Hide
|
|||
| Indication | Airway inflammation [ICD-11: CA05; ICD-10: J00-J99; ICD-9: 460-519] | Phase 1 | [1] | |
| Fibrosis [ICD-11: GA14-GC01; ICD-10: L90.5; ICD-9: 709.2] | Investigative | [2] | ||
| Company |
Moerae Matrix Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02515396) Phase 1a Study in Healthy Smokers to Investigate the Effect With MMI-0100 on Airway Inflammation in Induced Sputum After Challenge With Inhaled Lipopolysaccharide (LPS). U.S. National Institutes of Health. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2094). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.